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ABSTRACT AND GOALS OF THE THESIS 
 
Recently we have shown that a number of murine tumors arising from mice of 
the Balb/c (MHC H-2d) strain, induced to express MHC class II molecule after 
transfection with CIITA (MHC class II transactivator) ( Accolla R.S. et al. 1986) 
can be rejected effectively, generating tumor specific T helper cell (TH) 
triggering, immunological memory and protection even against parental tumor 
(Meazza R. et al. 2003 ; Frangione V. et al. 2010; Mortara L. et al. 2006) . The 
aims of my PhD thesis were:  a) - to assess whether the same results can be 
extended to tumors of different MHC background (H-2b); b) - to investigate, 
using knock-out C57Bl mice for dendritic cells, whether CIITA transfected 
tumor cells can act as “surrogate  APC” for their tumor antigens in vivo. To this 
end, LLC (Lewis lung carcinoma, H-2b) cells were stably transfected with 
CIITA and selected for expression of MHC class II molecules. Parental tumor 
cells and CIITA-transfected cells (LLC-CIITA) were injected  subcutaneously 
into C57/BL6 mice and tumor take and growth kinetics were assessed. Mice 
injected with LLC-CIITA cells were tumor-free for longer time than mice 
injected with parental tumor cells. The growth kinetics and the size of CIITA-
expressing tumors were significantly reduced compared to the parental tumor. 
Adoptive cell transfer of purified CD4+ TH cells from mice injected with LLC-
CIITA into naïve mice demonstrated that these cells were able to protect from 
LLC parental tumor growth. Taken together these results strongly suggest that, 
similarly to H-2d strain, also H-2b tumors can be rejected if expressing CIITA-
mediated MHC class II molecules, confirming the general applicability of our 
tumor vaccination model. To achieve the second goal we performed  in vivo 
experiments in a novel transgenic mouse model named CD11.c DOG, in which 
it is possible to induce a conditional depletion of dendritic cells (DC) by 
diphtheria toxin (DT) treatment. These mice express the diphtheria toxin 
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receptor (DTR) under the control of the promoter of the CD11c molecule, 
expressed preferentially in DC. Once injected with DT, dendritic cells are 
eliminated for the period of treatment up to 12 days. DT-treated CD11c.DOG 
mice where injected with LLC-CIITA tumor cells and tumor take and tumor 
growth was followed during time. We found that LLC-CIITA cells can be 
recognized and rejected better than parental tumor even in CD11c-DOG mice. 
These results suggest that CIITA-tumor cells may act in vivo as surrogate APCs 
for their own tumor antigens and trigger and adaptive immune response 
mediated by CD4+ TH cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
ABBREVIATIONS 
 
ACT   Adoptive Cell Transfer 
APC   Antigen Presenting Cell 
CIITA  Class II Transactivator 
CTL   Cytotoxic T Cell 
DC   Dendritic Cell 
DT   Diphteria Toxin 
DTR   Diphteria Toxin Receptor 
HLA   Human Leukocyte Antigens 
IFN-γ   Interferon- γ 
li   Invariant chain 
LLC   Lewis Lung carcinoma  
MDSCs  Myeloid-derived suppressor cells 
MHC    Major Hystocompatibility Complex   
TAA   Tumor associated antigen 
TH   T Helper cell 
TIL   Tumor- Infiltrating Lymphocytes 
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1 INTRODUCTION 
 
1.1 The Innate and Adoptive Immunity 
 
The immune system is a complex network of interacting cells, cell products, and 
cell-forming tissues that work together to protect the body against attacks by 
“foreign” invaders. The targets of the immune system are primarily organisms 
such as viruses bacteria, parasites. The immune  system encompasses various 
types of cells including T and B lymphocytes capable of specifically recognize 
antigens via their clonotypically distributed receptors (adaptive immunity), as 
well as other hemopoietic derived cells such as macrophages, dendritic cells, 
granulocytes and NK cells (innate immunity). In the adaptive immunity, B cells 
are responsible of producing and secreting antibodies that circulate in the blood  
and bind to antigens on infectious agents as these molecules are primarily 
responsible for protection against bacteria and viruses. This interaction can 
result in direct inactivation of the microorganism or activation of a variety of 
inflammatory mediators that will destroy the pathogen (Fig. 1). T cells are a 
subset of lymphocytes that undergo differentiation during an immune response 
and develop into several subpopulations of effectors. We distinguish two major 
types of T cells. Helper T cells (TH) expressing the CD4 cell surface marker are 
the primary cells involved in the recognition of antigen presented by HLA class 
II molecules. These cells are needed for maturation and differentiation of all 
other cells of adaptive immunity. Cytolytic T cells (CTL) expressing the CD8 
cell surface marker develop into cytolytic effectors (CTL, cytolytic T  
lymphocytes) that attack and kill target cells directly. Targets for CTL include 
cells infected by viruses, as well as cells that have become cancerous. This arm 
of adaptive immunity is termed cell-mediated immunity. To initiate an effective 
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immune response, most antigens must be processed;  because they cannot react 
directly with cells of the immune system, the antigens must be shown or 
presented to the immune cells in a specific manner. This is  accomplished by 
antigen-processing and presenting cells (usually dendritic cells and 
macrophages), generally referred as APCs (Fig. 2). T cells develop in the 
thymus, and here they acquire their competence and specificity by recognizing 
self antigens presented via the MHC molecules expressed by the individual. 
CD4+ TH cells become restricted by MHC class II molecules and CD8+ T cells 
become restricted by MHC class I molecules. Cells recognizing cell constituents 
with high affinity are deleted in the thymus (central tolerance) and only self-
restricted T cells with low affinity are matured and exported in peripheral 
lymphoid organs.   
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(From Glenn Dranoff, Nature Reviews Cancer 2004) 
 
Figure 1. Diagrammatic representation of Innate and Adaptive Immunity. 
 
 
 
 
The innate immune response functions as the first line of defence against infection. It 
consists of soluble factors, such as complement proteins, and diverse cellular 
components including granulocytes (basophils, eosinophils and neutrophils), mast cells, 
macrophages, dendritic cells and natural killer cells. The adaptive immune response is 
slower to develop, but manifests as increased antigenic specificity and memory. It 
consists of antibodies, B cells, and CD4+ and CD8+ T lymphocytes. Natural killer T cells 
and T cells are cytotoxic lymphocytes that straddle the interface of innate and adaptive 
immunity. 
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(From Janeway CA Jr, Travers P, Walport M, Shlomchik MJ, 2005.) 
 
Figure 2 . Humoral and cell-mediated immunity 
TH cells has a central role in immune response. TH cells recognize MHC II-restricted antigen 
on the surface of APC (e.g. macrophage) inducing the activation of CTL and B lymphocytes. 
CTL proliferate and differentiate into memory and/or  effector CTL that kill infected and 
cancer cells. B cells proliferate and differentiate into memory B lymphocyte and/or  plasma 
cells secreting antibodies. 
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1.2 MHC and CIITA 
 
Class I and class II MHC molecules share some structural features which are 
essential for the presentation of peptides and antigen recognition by T 
lymphocytes. Via their T cell receptor (TcR), CD4 T lymphocytes selectively 
recognize antigenic peptides bound to MHC class II molecules whereas CD8 T 
cells recognize antigenic peptides bound to MHC class I molecules. Class I 
molecules are formed by two non-covalently linked polypeptide chains: an 
MHC-encoded α chain (or heavy chain) of 44-47 kDa and a non-MHC encoded 
subunit, non transmembrane, non covalently bound to α-chain, of 12 kDa called 
β2-microglobulin (invariant but essential).  Each α chain is oriented in such a 
way that about three quarters of polypeptide extend into the extracellular milieu; 
a short hydrophobic segment crosses the cell membrane and the terminal 
carboxylic acid is localized inside the cell. The N-terminal domains α1 and α2 
present the polymorphic residues that contribute to the variability of class I 
alleles and form a platform consisting of a leaflet of β antiparallel strands, which 
support two parallel strips of α-helix. This set constitutes the pocket able to bind 
peptides of 8-11 amino acids in a flexible extended conformation; the pocket 
ends are closed in such a way that do not accommodate large peptides. This 
pocket will interact with the TcR expressed on the surface of CTL. The α3 
domain of the α chain is conserved in all class I molecules. This segment 
contains the binding site for the CD8 molecule expressed on CTL. Class II MHC 
molecules are composed by two non-covalently associated polypeptide chains, 
an α chain and a β chain. Unlike class I molecules, the genes that code for both 
chains are polymorphic. The amino terminal segments α1 and β1 form the 
peptide binding site. The ends of the pocket are open; this implies that class II 
molecules bind peptides larger (10-30 aa) than those of class I. α2 and β2 
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segments of the class II molecules, as the segment α3 and β2-microglobulin of 
MHC class I, are folded in Ig domains that do not vary substantially between the 
different alleles. The basic characteristics of both MHC class I and class II 
molecules are summarized in Figure 3. The gene encoding MHC molecules are 
located in human chromosome 6 (the HLA system) and in murine chromosome 
17 (H-2 system) (see Table 1 and Figure 4). Polymorphic human class I 
molecules are encoded by at least three loci designated : HLA-A, HLA-B, HLA-
C whereas class II molecules are encoded by six loci divided in three subloci: 
HLA-DR, HLA-DQ, HLA-DP. The mouse MHC region, designated H-2, is 
organized similarly to human MHC region. Mouse class I equivalents include H-
2K,-D and-L, whereas class II is made up of  at least four loci organized in two 
subregions, A and E subregions. H-2d and H-2b haplotypes have different 
numbers of class I and class II genes. Most interestingly, mice of the H-2b 
haplotype have class I K and D products but they miss L products. Furthermore 
H-2b haplotypes do not express the MHC class II molecule of the E locus 
because they do not express the EA gene encoding the alpha chain. While MHC 
class I gene products are expressed in virtually all cells, MHC class II gene 
products are expressed in a limited set of cells, and particularly in cells that 
serve as antigen presenting cells for CD4+ TH cells. Many other genes, non 
polymorphic in nature, are located within the MHC system of both mouse and 
human, and interestingly their products are mostly correlated with the function 
of the immune system. Thanks to their location these genes can be regulated in a 
coordinated manner. TAPBP gene  codes for tapasin, a chaperone protein; LMP 
gene codes for LMP2 and LMP7, two proteosome subunits, and TAP gene code 
for proteins Transporters associated with Antigen processing. All these proteins 
are essential for a normal antigen presentation and MHC- I expression. The 
expression patterns of MHC class  I and MHC class II molecules and their cell 
biology reflect their different roles (Table 1 and Fig. 4). MHC class I molecule 
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present endogenously synthesized antigens, e.g. viral proteins to CD8+ T cells. 
MHC class II molecules present exogenously derived proteins, e.g. bacterial 
products or viral proteins from phagocytosed viruses to CD4+ T cells. 
Expression of MHC class II molecules is exquisitely controlled at the 
transcriptional level and a large set of proteins interact with promoters of class II 
genes. The most important is the class II transactivator (CIITA), a master 
controller that orchestrates expression but does not bind directly to the promoter. 
(Ting et al., 2002). The MHC II transactivator was identified and characterized 
by a somatic cell approach. After generation of a somatic mutant (RJ 2.2.5), 
negative for MHC class II expression (Accolla R.S. et al.,  1983), somatic 
complementation with murine MHC class II positive cells demonstrated the 
existence of a dominant locus, encoding the trans-acting activator. This locus 
was mapped to mouse chromosome 16 and designated Air-1 (Accolla R.S.et al. , 
1985; Accolla R.S et al. , 1986) and the corresponding human locus designated 
AIR-1. Seven years later, the product of the AIR-1 locus was cloned by a gene 
complementation approach and named CIITA (Steimle et al., 1993). It is now 
well established that transcription of the AIR-1 gene is regulated by multiple 
promoters. Four promoters – referred to as pI, pII, pIII and pIV - have been 
defined. Each of these promoters is responsible for distinct tissue specific 
expression modes of CIITA. Promoters pI and pIII are responsible for myeloid 
and lymphoid specific expression patterns, respectively. A specific role for pII is 
not currently known. Promoter pIV is the major IFN-γ responsive promoter 
functioning in non-hematopoietic cells ( Reith and Boss, 2008) (Fig. 5 ) . Unlike 
other protein factors that directly bind DNA and have ubiquitous expression, 
CIITA has tissue-specific expression and is always associated with the 
expression of class II genes (Harton JA, 2000). CIITA protein consists of an  
acidic transcriptional activation domain, a phosphorylation and dimerization 
domain (PS/T)  (Tosi et al. Embo Journal, 2002), a GTP binding domain and a 4 
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LRRs (leucine-rich repeats) (Fig. 6). The protein is located mostly in the 
nucleus and acts as a positive regulator of class II major histocompatibility 
complex gene transcription. By binding GTP, CIITA facilitates its own transport 
into the nucleus. Once in the nucleus it does not bind DNA. In fact CIITA 
integrates the function of several DNA-binding proteins with specific 
characteristics. By interacting with the RFX protein complex (RFX5, RFXANK, 
RFXAP), the NF-Y complex (NF-YA, B, C) and CREB, it facilitates the 
assembly and the binding of these complexes to class II promoter. By interacting 
with the histone acetyl transferases CBP and pCAF, it facilitates the remodeling 
of chromatin around the promoter. By interacting with TAFs and with the P-
TEFb (Cyclin T1-CDK9) complex, CIITA facilitates the initiation and the 
elongation of transcripts, respectively (see Fig. 5).  
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(Modified from A.K. Abbas, A.H. Lichtman, 2003) 
 
Figure 3. Structures of Histocompatibility molecules and of peptide binding to MHC 
molecules. 
 
(From A.K. Abbas, A.H. Lichtman, 2003) 
            Table 1.  Expression and distribution of MHC molecules in different cell types 
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(Modified from A.K. Abbas, A.H. Lichtman, 2003) 
Figure  4. Schematic representation of Human (HLA) and Mouse (H-2) MHC regions. 
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(From Reith W. and Boss J M., 2008 ) 
Figure 5. The promoter of MCH class II gene. For further explanation see the text. 
 
 
 
 
(From Ting JP. and Trowsdale J. ,  2002) 
Figure 6.  The structure of CIITA protein. For further explanation see the text.  
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2. ANTI-TUMOR IMMUNITY 
 
2.1 Causes of scarce and insufficient 
response against the Tumors 
 
Although the host can mount an immune response against cancer cells, the fact 
that the tumor takes off in cancer patients demonstrates that tumor may elude 
immune defences (Vesely M. et al., 2011; Rosenberg SA. et al., 2004) .Tumors 
are complex tissues. They are composed of tumor cells, tumor stroma and in 
many cases of a series of blood-derived infiltrating leukocytes including cells of 
innate and adaptive immunity. It has been found that tumor-infiltrating 
leukocytes, including neutrophils, macrophages, mast cells, eosinophils 
(components of an heterogenous family of myeloid cells which can acquire 
inhibitory activity on immune lymphocytes, the so-called Myeloid-Derived 
Suppressor cells (MDSC)  (Gabrilovich DI . et al. 2012) as well as T cells with 
CD4+/CD25+ phenotype and suppressive function on helper and effector T 
cells, designated regulatory T cells (Tregs) (Sakaguchi S. et al. 1995; Nishikawa 
H. and Sakaguchi S., 2010), may cooperate in favouring, instead of 
antagonizing, tumor growth. These findings have created a diffuse belief that 
pro-tumor polarization of the innate and adaptive immunity is the cause for 
tumor cells to survive, replicate and spread (Mantovani A. and Sica A. , 2010; 
Ruffell B. et al. 2009). With the final goal to generate a stronger and sustained 
adaptive immune response against the tumor that may overcome the intrinsic 
difficulties of poor immunogenicity of TAA and the ostile tumor 
microenvironment, and assuming that the most potent anti-tumor effector is the 
CTL, many investigators have purified CTL-defined antigens, particularly from 
tumor tissues and used them as vaccine. However in most studies the CTL 
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responses were weak and unable to control tumor growth and metastasis 
(Rosenberg SA et al.,2008). Beside the reasons describe above, additional 
important elements did come into play. For example the frequent loss or reduced 
expression of MHC-I molecules in tumor cells which prevents TAA presentation 
to CTL (Kageshita T. et al. 1999, Garrido F. et al. 2010; Ossendorp F. et 
al.1998), and importantly the poor tumor-specific, MHC-II-restricted T cell help 
generated in tumor-bearing patients. The latter element is of fundamental 
importance because TH cells are required for optimal induction of both humoral 
and cellular effector mechanisms and particularly for CTL maturation, clonal 
expansions and acquisition of cytolytic function. TH cell triggering requires 
recognition of antigenic peptides presented by MHC-II molecule expressed on 
professional antigen presenting cells (APC) including dendritic cells (DC), 
macrophages and B cells. Preventing and/or inhibiting the  phase of MHC-II-
dependent tumor antigen presentation to and/or activation of TH cells would 
thus be an effective strategy to block the adaptive anti-tumor immune response 
from its beginning.  
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3  OUR APPROACH 
 
3.1 Previous Results 
 
The approach followed by our laboratory to obtain an optimal TH anti-tumor 
response is based on the concept that if MHC-II molecules can be expressed in 
tumor cells (most tumors do not express MHC class II) these cells may function 
as surrogate APC for their own tumor antigens and thus trigger an effective 
immune response. To this direction, cells were engineered with the cDNA 
coding for CIITA. Indeed we demonstrated that CIITA-induce MHC class II 
positive tumor cells can be recognized in vivo and elicit both tumor-specific 
CTL and, more importantly, CD4+ TH cells (Meazza et al., 2003; Mortara L. et 
al., 2006; Mortara L. et al., 2009; Frangione V. et al., 2010;). This approach 
has shown promising results in a series of tumor cell lines from mice of Balb/c 
strain (H-2d). CIITA transfected tumors of distinct histological origin (WEHI 
fibrosarcoma, C51 colon adenocarcinoma, RENCA renal adenocarcinoma, TS/A 
mammary adenocarcinoma) can be rejected effectively generating tumor 
specific T helper cell (TH) triggering, immunological memory and protection 
even against parental tumor (Fig. 7). 
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(From V. Frangione, PhD Thesis at the University of Insubria, 2008) 
Figure 7.  Anti -tumor Adaptative Immune Response. 
Tumor cell stably transfected with CIITA and expressing MHC II molecules is depicted here 
as a possible antigen-presenting cells (APCs), presenting MHC II-restricted tumor antigen. 
Helper T cells recognize these tumor antigens, with the help of CD4 co-receptor (CD4+) 
expression. The activation of a naïve helper T cell causes it to release cytokines and other 
stimulatory signals that determinate the activation of CTL that lyse target tumor cell 
(established) and B cells that produce antibodies (not yet proven).  
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3.2  Present Thesis Approach 
 
The main purposes of my thesis where two fold. First to validate the approach of 
in vivo immunogenicity and generation of a protective anti-tumor immune 
response with CIITA-tumor cells in a mouse strain of different genetic 
background. Second, to define more stringent methodologies for assessing the 
real APC function in vivo of CIITA-tumor cells and particularly the possibility 
that these cells may indeed prime naïve CD4+ TH cells to become anti-tumor 
specific T cells without the participation of classical professional APCs. As 
tumor model system we used the Lewis Lung Carcinoma (LLC) of  C57BL/6 
mouse origin (H-2b).  LLC cells were stably transfected with the cDNA coding 
for CIITA and used as prophylactic cancer vaccine. The results presented here 
demonstrate that a significant percentage of mice injected with LLC-CIITA cells 
rejected the tumor and an high percentage  remained tumor-free for a longer 
time than mice injected with parental tumor cells. Furthermore, the growth 
kinetics and the size of CIITA-expressing tumors are significantly reduced 
compared to the parental tumor. CD4+ and CD8+ lymphocytes isolated from 
spleen of mice rejecting the CIITA-tumor were able to protect or strongly retard 
the growth of parental LLC tumor cells in naïve recipients, demonstrating the 
importance of inducing a TH cell response for the generation of adaptive anti-
tumor immunity. Furthermore, the use of a transgenic H-2b mouse model in 
which a conditioned depletion of professional APCs (dendritic cells) can be 
generated, demonstrated that CIITA-tumor cells could still be rejected in vivo 
because of specific immunity, strongly suggesting that these cells act as 
surrogate APC for priming and induction of  anti-tumor TH cells.  
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4. MATERIALS AND METHODS 
 
4.1 Cell culture and in vitro LLC cells growth kinetics 
 
The murine tumor cell line LLC (Lewis Lung Carcinoma) was cultured  in 
DMEM medium supplemented with L-glutamine and 10% of heat-inactivated 
FBS in a 5% CO2 atmosphere at 370C. The in vitro growth kinetics in absence 
and in presence of G418 (the selective neomycin antibiotic for growing CIITA 
transfectants) was assessed by plating the cells at fixed numbers and by counting 
them at fixed times. The dose of G418 to be used for selecting the transfectants 
was assessed in similar way.  
 
 
4.2 Short-term treatment of parental LLC cells with 
IFN-γ and evaluation of surface MHC-I and MHC-II 
molecules expression 
In order to assess the steady state and the inducible (IFN-γ) MHC class I and 
class II expression in LLC parental cells (LLC pc), the cells were plated at 
different cell number in each well of  a six well plate. After 24 hours 300 U/ml 
of IFN-γ was added to each well. After 48h, 72h and 96h of IFN-γ treatment, the 
cells were tested for MHC-I and MHC-II cell surface molecules expression by 
immunofluorescence and cytofluorometry in a Fluorescence activated cell sorter 
(FACS) Becton-Dickinson Aria.II instrument using B22.249 biotinalated (anti-
H-2Db) and AF6120.1 (anti-H-2 Ab) antibodies and  as a second step reagent a 
FITC Streptavidin (Biolegend, Mylan , Italy) antibody.  
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4.3 Plasmids, CIITA transfection and cell surface 
phenotyping 
 
The full-length human CIITA cDNA was obtained by preparative proof-reading 
PCR (Fusion Taq; Finnzymes, Helsinki, Finland) from pREP10-CIITA plasmid, 
(Sartoris et al. 1996). Forward and reverse primers bear Xho-I linker tails used 
to subclone the PCR product into the pLXIN2.ape retroviral vector (obtained 
from Dr. Antonio Daga, Department of Translational Oncology, IST-National 
Cancer  Research Institute, Genoa, Italy) , modified from pLXIN retroviral 
vector (Clontech, Milan, Italy) to include additional restriction sites in the 
multiple cloning sequence. The resulting pLXIN-CIITA  vector was transfected 
by using Lipofectamine TM 2000 (Invitrogen SRL, San Giuliano Milanese, Italy), 
a molecule composed by a cationic tail (to which it binds the DNA) and a lipid 
region (which facilitates the DNA entry across the plasma membrane). Briefly, 
parental LLC tumor cells were transfected with 2 µg of plasmid or with pLXIN 
empty vector as a control. The plasmid carries a gene conferring resistence to 
neomycin. After transfection, the cells were cultured in DMEM medium 
supplemented with 1mg/ml of  neomycin (G418, Sigma, Milan, Italy). Both 
trasfectants were tested for MHC-II surface expression by cytofluorimetry using 
anti-mouse I-Ab antibody AF6120.1  To obtain LLC transfectants with a stable 
and high expression of MHC-II molecules induced by CIITA, cells were sorted 
several times and subsequently cloned by limiting dilution procedures. Most of 
the studies described in this work were performed by using the LLC-CIITA 
transfectant clone E10. 
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4.4 Murine Models 
 
Five to eight week-old  C57BL/6 (H-2Kb)  mice were purchased from Charles 
River - Research Models and Services (Calco, Italy). CD11c-DOG transgenic 
mice were kindly provided by Dr Günter J. Hämmerling (German Cancer 
Research Center DKFZ Heidelberg). CD11.c-DOG transgenic mice were 
generated by gene targeting using a fusion construct composed of the DNAs for 
the human DTR, ovalbumin fragment aa 140–386, and eGFP inserted at the start 
codon of the CD11c gene The eGFP component of the fusion protein failed to 
give a fluorescence signal, whereas the ovalbumin protein was expressed in 
dentritic cells (DC) ( Fig.17). CD11c-DOG heterozygous knockout mice were 
propagated by crossing heterozygous knockout males to C57BL/6 females. Mice 
were held under specific-pathogen-free conditions at the animal facility of the 
University of Insubria, and experiments were performed according to 
institutional guidelines and regulations. Genomic DNA was isolated from mouse 
tails using SNET solution (Tris-HCl pH 8.0 1.0M, EDTA pH 8.0, NaCl 5 M, 
SDS 10% ) Proteinase K 20mmg/ml (Sigma, Mylan, Italy) for 3 hrs at 50 oC and 
subsequently, using phenol chloroform extraction method. Genotyping was 
carried out by PCR from genomic DNA of tail biopsies using the following 
primers for OVA:  
5’-AACCTGTGCAGATGATGTACCA-3’(sense) and  
5’-GCGATGTGCTTGATACAGAAGA-3’(antisense). β−2 microgobulin was 
used as housekeeping gene and detected with the following primers:  
ßm: 5’-CACCGGAGAATGGGAAGCCGAA-3’(sense) and  
5’-TCCACACAGATGGAGCGTCCAG-3’(antisense).  
Amplified DNA samples were analyzed by 1,5%  agarose gel electrophoresis 
and photographed (Fig. 18).  
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4.5  In vivo injection of LLC parental and LLC-CIITA 
tumor cells and determination of their growth kinetics 
 
Groups of  10 C57BL/6 female  mice, aged five to six weeks,  were injected 
subcutaneously in the right flank with 3 x105 LLC parental cells (LLCpc),  LLC 
transfected with empty vector (LLC-Lxin),  or  transfected with CIITA (LLC-
CIITA). As control, a group of 5 mice were injected using the same number of 
LLC cells transfected with the empty vector. Tumor size  was measured using 
caliper at weekly intervals and was expressed as a multiple of the wider and 
smaller tumor diameters. 
 
4.6  Ex vivo tumor cell culture and  MHC-II cell surface 
phenotyping 
 
To assess the stability of the MHC class II phenotype in vivo LLCpc and LLC-
CIITA tumors were excised and collected in DMEM medium supplemented 
with penicillin and streptomycin in a 50 ml centrifuge tube and kept on ice prior 
to processing in a sterile tissue culture hood. Each tumor was mechanically 
dissociated using a 70 µm filter, sterile needle, scalpel and  pestle. The cell 
suspension was collected in a tube and centrifuged. The cell pellet was 
resuspended  in complete DMEM medium  supplemented with specific 
antibiotics and  cultured in a 5% CO2 atmosphere at 370C. Quickly after 
establishing the cell culture, expression of MHC-II cell surface molecules was 
analyzed as described above.  
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4.7 Conditional DC cells depletion in CD11c.DOG mice 
 
For systemic DC depletion, CD11c.DOG mice were injected i.p. with 8ng/gr of 
body weigh (gbw) of  diphtheria toxin (DT) (Sigma) dissolved in PBS. All 
experiments were performed on heterozygous CD11c.DOG mice of about 2 
months of age. Wild-type C57BL/6 mice of the same litter and age were used as 
controls. Conditional DC depletion was tested in the spleen. After 48h of DT 
treatment, mouse spleens were harvested and collected in DMEM medium 
supplemented with penicillin and streptomycin, mechanically processed using a 
40 µm filter, sterile needle and pestle. The cell pellet was collected by 
centrifugation, and ACK solution was added to lyse the erythrocytes. The 
supernatant was discarded and the pellet was then resuspended in DMEM 
medium. Splenocyte viability was measured using trypan blue. Splenocytes 
were phenotypically analyzed by direct immunofluorescence and FACS 
analysis.  
 
 
 
 
4.8  Cell surface phenotype of mouse splenocytes 
Spleen cells from normal or tumor bearing mice were assessed by FACS for the 
expression of several cell surface markers by using directly fluorochrome-
labeled antibodies and corresponding isotype control antibodies. The relevant 
cell surface markers assessed were: CD11c, CD4, CD8 and CD19.    
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4.9 Adoptive Cell Transfer  
 
In order to evaluate the ability of splenocytes from CIITA-tumor vaccinated 
mice   to confer protection to naïve syngeneic recipients  the spleen was isolated 
under sterile conditions, dissociated with a sterile syringe plunger in cell strainer 
with 40 µm nylon mesh (BD Milan, Italia), treated with ACK buffer (150 mM 
NH4Cl; 10 mM KHCO3; 0.1 mM EDTA pH7.4) to deplete red blood cells. CD4+ 
and CD8+ cells were purified from the total spleen suspension  using the CD4+ 
or CD8+ T Cell Isolation Kit II MACS (Miltenyi Biotec GmbH, Germany), 
according to the manufacturer’ instruction. Purification was by positive selection 
of non-CD4 or non CD8-positive population and collection of the  relevant flow-
through CD4+ or CD8+ populations, respectively. Purity was ≥ 90%, as 
assessed by immunofluorescence and FACS analysis. Total splenocytes, purified 
CD4+ or  CD8+ cells from either immunized or  naïve mice were separately 
mixed with parental tumor cells in RPMI 1640. Groups of  naïve C57BL/6 mice 
(5 to 8 weeks-old ) were s.c. injected with 5x104 parental tumor cells plus total 
splenocytes (ratio 1:20) or purified CD4+ or CD8+ cells maintaining the same 
proportion observed in the total spleen. Tumors were measured weekly by 
caliper and sizes recorded as the tumor area (mm2). 
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4.10 Evaluation of CD11b+ and Gr1+cells 
 
Several studies have shown the presence of splenomegaly and  accumulation of 
CD11b+ and Gr1+ cells in the spleen of tumor-bearing mice. In order to 
investigate this aspect in our tumor vaccination model, splenocytes from LLC-
CIITA tumor-free mice, as well as from LLCpc tumor-bearing mice were 
isolated from spleens. Specifically, each spleen was harvested under sterile 
conditions, and spleen cells prepared as described above. Single cell suspensions 
were incubated with anti-Gr1 or anti-CD11b specific antibodies and analyzed by 
FACS. To assess the function of CD11b+/Gr1+ cells two groups of  five 
C57BL/6 mice were injected with 1x106 FACS-sorted CD11b+Gr1+ cells, mixed 
with either 1x105 LLCpc or LLC-CIITA cells (ratio 10:1). Control groups were 
injected with the same number of LLCpc or LLC-CIITA cells alone. Tumor size 
was measured weekly by caliper and sizes recorded as the tumor area (mm2). 
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5. RESULTS 
 
5.1  In vitro characterization of parental and CIITA-
transfected LLC cells 
 
As preliminary study to understand the biological properties of the tumor cell 
line analyzed in this investigation, we first determined the duplication time in 
vitro of LLC cells. This was found to be of 22 hours (Fig.9). 
Subsequently, we assessed by flow cytometry the MHC class I and class II cell 
surface phenotype of parental LLC cells. MHC class I molecules were expressed 
(Fig.10A), whereas MHC class II molecules were not expressed (Fig.10C). 
Lack of expression of MHC-II molecule could not be rescued even after 
treatment with 300 U/ml of IFN-γ (Fig.10D), a cytokine which strongly increase 
MHC-II expression by acting on the upregulation of transcription of CIITA-
encoding AIR-1 gene (Fig.8). IFN-γ is known to upregulate also MHC class I 
expression (Yang I.et al.,2004). In this case the IFN-γ treatment indeed increased 
MHC-I expression (Fig.10B). 
Based on the above results, we investigated whether stable transfection of 
exogenous CIITA may induce MHC class II gene expression. CIITA cDNA was 
inserted into a vector containing a gene conferring resistance to neomycin 
(G418). Thus we first assessed the minimal dose of G418 capable to kill all 
parental LLC cells. The concentration of 1mg/ml was sufficient to kill 100% of 
the cells in 5-7 days. Stable CIITA plasmid and control plasmid transfectants 
were established by Lipofectamine in presence of the above concentration of 
G418 (Fig.11B and 11C). Exogenous CIITA was able to induce expression of 
MHC class II genes and corresponding molecules indicating that parental LLC 
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cells do not have an intrinsic defect in the transcription of these genes, provided 
CIITA is expressed (Fig.11C). CIITA-transfectants expressing MHC-II 
molecules were further enriched by sorting, followed by cloning in limiting 
dilution conditions. LLC-CIITA clone E10 was chosen for further studies 
(Fig.11D).  
 
5.2  In vivo studies of parental and CIITA-transfected 
LLC cells in C57Bl/6 mice 
 
LLC cells transfected with CIITA display a reduced tumorigenicity in vivo. In 
fact, mice injected with LLC-CIITA cells were tumor-free for longer time than 
mice injected with parental tumor cells. After two weeks from LLCpc injection 
100% of mice developed palpable tumors while only 60% developed tumors 
after injection of LLC-CIITA. Importantly, 40% of LLC-CIITA injected mice 
remained tumor-free after the 28 day observation period (Fig.12A). Of 
relevance, the growth kinetics and the size of CIITA-expressing tumors were 
significantly reduced compared to parental tumors. In fact, after 14 and 21 days 
from LLCpc cells injection, mice had an average tumor size double than mice 
injected with LLC-CIITA. 28 days after injection, the average size of LLCpc 
tumors was three times higher than LLC-CIITA tumors  (Fig.12B). The fact that 
LLC-CIITA cells had a reduced growth but were not completely rejected by the 
syngeneic host, as it was found for other tumor models (Meazza R. et al. 2003; 
Frangione V. et al. 2010) suggested that the immune response against CIITA-
tumors was not entirely protective. In order to investigate this aspect in more 
detail, we analyzed the tumor  tissues originated from LLCpc or LLC-CIITA 
injection. As expected ex vivo parental LLC tumor cells  were MHC-II negative 
(Fig.13D) ; instead, ex vivo LLC-CIITA tumor cells although still positive for 
34 
 
MHC class II, displayed a reduced expression with respect to the original 
injected cells (compare histograms in Fig.13A and 13C).  This may partially 
explain why LLC-CIITA, although immunogenic, were not fully rejected in 
vivo.  
 
5.3   Analysis of the protective potential of spleen cells 
and T cell subpopulations from CIITA-injected mice by 
Adoptive Cell Transfer 
 
In order to evaluate the ability of splenocytes from CIITA-tumor vaccinated 
mice to confer protection from tumor growth, adoptive cell transfer experiment 
were set up. C57BL/6 naïve female and male mice were s.c. coinjected with 
5x104   LLC parental tumor cells mixed with either total splenocytes, purified 
CD4+ or CD8+ cells from immunized mice (still tumor free at 28 days post-
CIITA-tumor injection) or from  naïve control mice. All mice coinjected with 
LLC parental tumor cell and total splenocytes from immunized mice were tumor 
free up to 28 days. Moreover 40% and 20% of mice coinjected with LLC cells 
mixed with CD4+ or  CD8+ cells from immunized mouse, respectively, were 
tumor free at the same time. Importantly, 20% of mice coinjected with LLC 
cells mixed with CD4+ from immunized mice never developed tumor. Instead, 
all mice of the corresponding control groups developed tumors 21 days after 
injection (Fig.14A and 14C). Interestingly, mice injected  with LLC cells mixed 
with total splenocytes, purified CD4+ or  CD8+ cells from immunized mice 
showed an average tumore size almost three times smaller than corresponding 
control mice  (Fig.14B and 14D).  
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Taken together these results indicate tha a)- immune spleen cells from LLC-
CIITA vaccinated mice can protect naïve mice from parental tumor take in 
adoptive cell transfer approaches; b)- both CD4+ and CD8+ T cells can act as 
effectors against the tumors if previously triggered by MHC-II positive tumor 
cells.  
 
5.4  Animals injected with CIITA-tumors profoundly 
modify the tumor-related microenvironment 
 
Tumor development and its growth are  accompanied by a series of homeostatic 
modification in the host that often result in the generation of a pro-tumor 
microenvironment favouring tumor expansion and spread, while antagonizing 
anti-tumor immune responses. Among hemopoietic derived cells that are 
affected toward a pro-tumor growth function, an important role is played by so 
called myeloid-derived suppressor cells (MDSC), a population of CD11b+/Gr-1+ 
myeloid cells expanded dramatically during tumor progression. MDSC can 
inhibit the function of  T cells and dendritic cells, contributing to tumor immune 
escape. We observed that LLCpc tumor-bearing mice had a dramatic 
splenomegaly, three to five times the volume of healthy mice. This 
splenomegaly was not observed or was only moderate in mice injected with 
CIITA-transfected tumors (Fig.15 top panels). Cell surface phenotype of the 
spleen cells showed that LLCpc tumor-bearing mice displayed a large 
population of  CD11b+/Gr-1+ cells, accounting for 30-50% of the total spleen. In 
naïve mice, this population accounted for only 2-3% of spleen cells. 
Interestingly, LLC-CIITA injected mice, which were protected from tumor 
growth had the same proportion of  CD11b+/Gr-1+  spleen cells as the naïve mice  
(Fig.15 bottom panels). Thus a large cell population with the phenotype of 
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MDSC is rapidly and massively accumulated in spleen cells of tumor-bearing 
mice but not in mice injected with LLC-CIITA tumor cells. These results 
suggest that CIITA-tumor cells can possibly affect both expansion and spleen 
accumulation of CD11b+/Gr-1+ contributing to tumor rejection. We further 
investigated whether these cells could bear functional importance in tumor 
development and/or in supppression of possible immune responses against the 
tumor. To investigate this aspect, two groups of C57BL/6 mice were coinjected 
with CD11b+/Gr1+ cells (derived from a spleen of LLCpc tumor-bearing mouse) 
mixed with LLCpc or LLC-CIITA tumor cells (ratio 10:1). All mice coinjected 
with LLCpc and CD11b+/Gr1+ cells developed palpable tumors ( 20-50 mm 2) 
within two-three weeks. The time of appearance of tumors was slightly 
accelerated with respect to the appearance of LLCpc tumors, although this result 
was not statistically significant. Of relevance, mice injected with either LLC-
CIITA mixed with CD11b+/Gr1+ or with LLC-CIITA alone displayed virtually 
the same tumor appearance and tumor growth kinetics.  At three weeks post-
injection all mice coinjected with LLC-CIITA and CD11b+/Gr1+ cells were 
tumor free,  and only 25 % of mice injected with LLC-CIITA cells alone 
developed tumor with an average size of 10 mm 2. Importanly, 35% and 50% of 
mice within these groups, respectively, did not develop tumors at all during the 
5 week observational period. Therefore, mice injected with LLC-CIITA mixed 
with CD11b+/Gr1+ cells were equally protected from tumor growth as the ones 
injected with LLC-CIITA alone (Fig.16A and 16B). 
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5.5  In vivo studies of parental and CIITA-transfected 
LLC cells in CD11c.DOG mice 
 
A crucial point of our approach is to define whether CIITA-tumor cells may 
directly act in vivo as surrogate APC for their own tumor antigens in place of  
professional antigen presenting cells (APC) like dendritic cells (DC), and in so 
doing trigger and prime naïve tumor-specific CD4+ TH cells. In order to better 
investigate this point we made use of the transgenic CD11c.DOG mice which 
can be deprived of DC by conditional treatment with Diphteria Toxin (DT) 
(Fig.19). Indeed treatment with DT resulted in the drastic reduction of the 
CD11c-high/MHC-II+ DC subpopulation (Fig.20). Moreover, DT treatment in 
CD11c. DOG mice caused a splenic reduction of  those proportionally low but 
existing B cells, CD4+ and CD8+ T cells which express high levels of  CD11c 
surface molecules. Interestingly DT treatment resulted in an increase of 
neutrophils as compared to control spleens.  
A protocol was then set up to analyze the behaviour of parental LLC or LLC-
CIITA tumor cell growth in these mice. CD11c.DOG mice were daily treated 
with DT for eleven days. After two days of treatment the mice were injected 
with  2x105  LLC-CIITA cells or LLCpc cells. DT-untreated mice were used as 
controls. Tumor size  was measured using a caliper at weekly intervals. As 
shown in Figure 11, CD11c.DOG mice depleted of  DC cells and injected with 
LLC-CIITA cells were tumor-free for a longer time than similarly treated  mice 
injected with LLCpc. In fact, three weeks after immunization, these mice 
showed an average tumor size of 20 mm2  ( Fig. 21F) ; in contrast, control group 
mice injected with parental LLC cells showed an average tumor size six times 
greater (120 mm2 ) (Fig. 21B). 
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Moreover, tumor growth in DT-treated mice injected with LLC-CIITA was even 
slower than the growth of LLC-CIITA tumors in DT-untreated mice (Fig. 21 D). 
The above experiment was conducted several time with similar results (see Fig. 
22). The above results indicate that the depletion of dendritic cells in CD11c. 
DOG mice does not affect the growth retardation of LLC-CIITA tumor and thus 
give support to the idea that the important APC in vivo that prime tumor-specific 
TH cells are indeed the CIITA-transfected, MHC class II-positive tumor cells. 
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6. DISCUSSION 
 
There are numerous evidences in favor of an immunological surveillance against 
tumors, in fact, several studies have reported tumor regression due to immune 
responses, at least in experimental animals  (reviewed in Dunn J.P. et al., 2004 ; 
Accolla R.S. et al., 2010), demonstrating that the immune system can be 
"educated" to selectively eliminate cancer cells. It is generally accepted that the 
in vivo adaptive anti-tumor immune responses are partially ineffective when 
CTL do not have sufficient support from TH cells that in order to be primed 
require the recognition of antigen presented by professional APC, like dendritic 
cells (Steinman RM and Banchereau J., 2007) The approach followed by our 
laboratory to obtain an optimal TH anti-tumor cells response is based on the 
concept that if tumor cells can optimally express MHC-II  molecules, these cells 
may function as surrogate APC for their tumor antigens and thus trigger an 
effective immune response. To obtain these  “optimally MHC-II expressing 
tumor cells”, tumor cells were engineered with the cDNA coding for CIITA 
(MHC class II transactivator) the major transcriptional activator of MHC class II 
genes, discovered in our laboratory (Accolla R.S. et al.,1986);). We chose this 
strategy in order to maintain the natural processing and surface expression of 
MHC class II molecules which do not take place when the cells are transfected 
with isolated alpha-beta MHC class II genes alone. Moreover, the expression of 
invariant chain (li) and other accessory molecules like DM, necessary for the 
correct physiology of antigen presentation, are induced and/or optimized by 
CIITA. This approach has shown promising results in a series of tumor cell lines 
from mice of Balb/c (MHC H-2d) strain. CIITA transfected tumors could be 
rejected effectively, generating tumor specific T helper cell (TH) triggering, 
immunological memory and protection even against parental tumor (Meazza et 
al.,2003; Mortara L. et al., 2006; Mortara L. et al., 2009; Frangione V. et al., 
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2010; see  also Accolla RS and Tosi G, 2012;  Accolla RS and Tosi G, 2013)  
Considering the genetic homogeneity of inbred strains and having in mind a 
possible application of this strategy to highly genetic diverse populations as  
humans, it was crucial to assess whether similar results could be extended to 
mouse strains with different background. The results presented in this thesis 
show that LLC tumor cells of the H-2b background could be rendered highly 
immunogenic and rejectable in vivo by CIITA-mediated gene transfer 
confirming the general applicability of our tumor vaccination model. In fact, the 
presence of CIITA-induced MHC-II molecules in tumor cells was instrumental  
to trigger antigen-specific antitumor response capable of protecting  in vivo  the 
vaccinated animals from tumor take, and, importantly, to protect them against 
the rechallenge with parental tumor cells. In LLC-CIITA vaccinated mice long-
lasting tumor-specific CD4+ TH  cells were generated that may protect naïve 
syngeneic C57BL/6 recipients from tumor take or significantly reduce tumor 
growth upon adoptive cell transfer. Although it was very suggestive from 
previous findings of our laboratory that tumor cells may act as APC in vivo, in 
the present study we provide the first evidence that CIITA-tumor cells act 
themselves as trigger of tumor specific TH cell priming in vivo and that this 
trigger does not require, or at least is not totally dependent from, dendritic cells 
the professional APC considered the major cell type responsible for TH cell 
priming. This evidence was obtained by taking advantage of a recently described 
transgenic mouse model, the H-2b CD11c.DOG mice,  in which a conditional 
knock-out of DC can be obtained by treatment with diphtheria toxin (DT). 
Indeed in DT-treated transgenic CD11c.DOG mice, originally shown by 
(Hochweller K.,2008) to be transiently deprived of  DC and confirmed here, 
LLC-CIITA tumor cells were strongly retarded in their growth, in some case 
fully rejected, with a pattern virtually superimposable to the one observed in 
DT-untreated, DC undepleted mice.   
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Thus tumor cells can act as APC for MHC-II-restricted TH cells in the absence 
of DC. Furthermore from an immunological point of view these results show 
that alternative mechanisms of antigen presentation for TH cell priming in vivo 
not only can occur but they can occur in milieus other than lymphoid tissues.  In 
LLC-CIITA vaccinated mice, long-lasting tumor-specific CD4+ TH  cells were 
generated that may protect naïve syngeneic C57BL/6 recipients from tumor take 
or significantly reduce tumor growth upon adoptive cell transfer. Vaccination of 
mice with LLC-CIITA tumor cells is instrumental also in reorienting the tumor 
microenvironment and the tumor-dependent extra-tumor microenvironment 
from a pro-tumor behavior to an anti-tumor behavior. This has been 
demonstrated by our previous work in the Balb/C system and further reinforced 
here by the unprecedented finding that myeloid-derived suppressor cells 
(MDSC) dramatically increased in LLCpc tumor-bearing mice virtually 
disappeared in CIITA-tumor vaccinated mice. Furthermore, MDSC did not exert 
their suppressive function in vivo on the onset of adaptive immunity triggered by 
CIITA-tumor  cells. In conclusion, these results open new ways for alternative 
strategies of anti-tumor vaccination and anti-tumor therapy based on the optimal 
activation of anti-tumor CD4+ TH cells  by CIITA-driven MHC-II-positive 
tumor cells. 
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7. FIGURES AND LEGENDES 
 
Fig.8  
Expression of the AIR-1 locus-encoded CIITA induces MHC-II expression in LLC 
tumor cells. 
 
 
Fig.9  In vitro growth curve of LLC cells. Data are expressed in the ordinate as a number of 
LLC tumor cells at different time intervals (days in the abscissa). The duplication time of 
LLC cells was 22 hours. 
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Fig. 10.  Induction of MHC molecules in parental LLC cells by IFN-γ treatment. Parental 
LLC cells were treated with 300 U/ml of IFN-γ and tested for MHC-I and MHC-II molecules 
surface expression by FACS using appropriate antibodies.A and C depict the results of the 
expression of MHC-I and MHC-II molecules, respectively, in untreated parental LLC cells. B 
and D depict the results of the expression of MHC-I and MHC-II molecules, respectively,  in 
parental LLC cells 96 hours after IFN-γ treatment. 
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Fig. 11.  MHC class II expression in LLC-CIITA trasfectants. Lewis Lung Carcinoma 
(LLC) cells were stably transfected with CIITA plasmid carrying the neomycin resistance 
gene (C and D) or  with the empty vector LXIN as a control (B). Stable transfectants were 
selected in DMEM medium added with neomycin (1 mg/ml) and analyzed for the expression 
of CIITA-induced MHC-II cell surface molecules with a specific anti-MHC-II FITC-labelled 
mAb (yellow histograms).Original LLC-CIITA transfectant population(C); selected LLC-
CIITA clone after cloning in limiting dilution conditions (D). 
 
 
        
 
MHC II 
MHC II MHC II 
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Fig. 12. Mice injected with LLC-CIITA cells are tumor-free for a longer time than mice 
injected with parental tumor cells. C57BL/6 mice were injected with either LLCpc or LLC-
CIITA E10 clone cells (five mice per group). A, percentage of tumor-free mice at different 
time intervals. One hundred percent of mice injected with LLC tumor cells developed 
palpable tumors within  2 weeks. Instead, 40% of mice injected with LLC-CIITA tumor cells 
were tumor free up to 4 weeks. B, LLC-CIITA tumors showed  an average tumore size  
significantly reduced  compared to parental tumor. 
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Fig. 13 Ex vivo tumors evaluation based on MHC-II molecules surface expression. LLC-
CIITA cells before mouse injection (A); ex vivo LLC-CIITA tumor cells (C). Parental LLC 
cells before mouse injection (B); ex vivo parental LLC tumor cells (D ). ex vivo Parental LLC 
and LLC-CIITA tumors of similar size were excised, four weeks after tumor injection, from 
C57BL/6 mice and put in culture. After 2 weeks, cell cultures were phenotypically analyzed 
by immunofluorescence and FACS for the expression of MHC-II cell surface molecules with 
a specific anti-MHC-II FITC- labeled mAb (yellow histograms). 
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Fig. 14. Role of total splenocytes and T lymphocyte subpopulation in anti-tumor 
immunity after CIITA-vaccine. 
Groups of five female C57BL/6 mice (5 to 8 weeks-old) were s.c. coinjected with 5x104 LLC 
parental tumor cells mixed with total splenocytes, purified CD4+ or  CD8+ cells from 
immunized mice or from a naïve mice (as a control). (A, C) Percentage of tumor-free mice at 
different time intervals. All mice coinjected with LLC parental tumor cells mixed with total 
splenocytes from immunized mice were tumor-free up to 28 days. 40% and 20% of mice 
coinjected with LLC cells mixed with CD4+ or CD8+ cells from immunized mice, 
respectively, were tumor free up to 28 days. Moreover, 20% of mice coinjected with LLC 
cells mixed with CD4+ from immunized mice never developed tumor. All mice of the 
corresponding control groups developed tumor 21 days after injection. (B, D) Mice injected  
with LLC cells mixed with total splenocytes, purified CD4+ or  CD8+ cells from immunized 
mice showed  an average tumore size  almost three times less than corresponding control mice 
groups. 
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Fig.  15. Phenotypic analysis of CD11b+ and Gr1+ cells in spleens from different origin. 
Upper panels: Photo of spleen harvested from LLC tumor-bearing mouse show an evident 
splenomegaly. The size is four times greater than spleens from  naïve and  LLC-CIITA tumor 
free mice. Lower panels: Citofluorometric analysis. Spleen cells from naïve, tumor-bearing 
and tumor -free C57BL/6 mice were isolated, as described in Materials and Methods, and 
stained using anti-mouse Gr-1 and anti-mouse/human CD11b antibodies. Spleen from LLC 
tumor-bearing mouse show a dramatic accumulation of CD11b+ and Gr1+ cells (blue gate), of 
very low proportion in naïve and LLC- CIITA tumor -free spleens. 
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Fig. 16. Evaluation of in vivo effects of  CD11b+Gr1+ cells when coinjected with LLC or 
LLC -CIITA tumor cells. 
Two groups of C57Bl/6 mice were coinjected with 1x10 6 CD11b+Gr1+ cells and 1x10 5 LLC 
or LLC-Lxin CIITA E10-A12 clone cells (ratio 10:1); control mice groups were injected only 
with1x10 5 LLC or LLC-Lxin CIITA cells.(A) Percentage of tumor-free mice at different time 
intervals. All mice  coinjected with LLC cells and CD11b+Gr1+ cells developed tumor up to 
two weeks and only 25% of corresponding control mice group were tumor free at the same 
time, but they also developed tumor after three weeks. Whereas, 100% of mice both  injected 
with LLC-CIITA mixed with CD11b+Gr1+cells or with LLC-CIITA alone were tumor free 
after two weeks. Importantly , 35% and 50% of mice of these groups never developed tumor, 
respectively.(B) Mice injected with LLC-CIITA mixed with CD11b+Gr1+cells or with LLC-
CIITA alone show an average of tumor size seven to twelve times less than corresponding 
control mice groups.  
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Fig. 17 Scheme of construct used to generate CD11c.DOG mice.  
A fusion construct consisting of the human DTR, an ovalbumin 140–386 fragment, and eGFP 
was cloned into a BAC under the CD11c promoter by homologous recombination. 
 
 
 
 
 
 
Fig. 18  CD11c.DOG mice genotyping  
PCR samples were loaded on 2% agarose gel and DNA was visualized under UV exposure. 
Lines: 1,2,3,5,8,10,12,14 and 15 correspond to heterozygous CD11c.DOG mice. β 
microglobulin was used as housekeeping gene 
 
 
 
Fig.19 Experimental Scheme of  DT administration in CD11c.DOG mice 
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Fig. 20.  Depletion of DC, B and T cells in CD11c.DOG mice after DT treatment. FACS 
dot blots of live splenocytes from untreated control mice (DT,left) or mice treated with DT 
(+DT, right). CD11c  expression and depletion or increase of   the   following   cell   types   
48   hrs   after   DT  administration  is   shown   (from   top   to   bottom):  cDC  (gated  on 
 live splenocytes), B cells  (gated on  CD19+  cells),  CD4  T  cells   (gated  on  CD3+  CD4+ 
cells),  CD8  T  cells  (gated  on  CD3+ CD8+  cells), granulocytes (gated on Gr-1+ cells)  
The  cut-off   point   for   CD11c expression   was   obtained   for   isotype-matched irrelevant 
antibodies. Groups of 2 mice were used. 
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Fig. 21.  Mice injected with LLC-CIITA cells  DT treated and untreated show a strong 
reduction of tumor size compared to corresponding control mice groups injected with parental 
tumor cells. (A) Percentage of tumor-free DT treated mice at different time intervals. CD11c.DOG mice 
injected  with 2x10 5 parental LLC cells developed palpable tumors within 2 weeks. (C)  50% of 
CD11c.DOG mice DT untreated and injected with LLC-CIITA cells were tumor free for 3 weeks, instead, 
25% of CD11c.DOG mice DT treated and  injected with the LLC-CIITA cells were tumor free up to 4 
weeks(E) . (B) CD11c. DOG mice injected  with parental LLC cells showed  an average tumore size  
strongly increased than mice injected with LLC-CIITA cells. ( D, F )  CD11c.DOG mice untreated and 
injected  with LLC-CIITA cells displaied an increase tumor growth compared to CD11c.DOG mice DT 
treated. Tumor size  was measured using caliper at weekly intervals and was expressed as a multiple of the 
wider and smaller tumor diameters. 
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Fig. 22. Mice injected with LLC-CIITA cells  DT treated and untreated show a strong 
reduction of tumor size compared to corresponding control mice groups injected with 
parental tumor cells. 
CD11c.DOG mice DT treated or untreated (CTRL) were injected  with 2x10 5 LLC or LLC-
Lxin CIITA E10-A12 clone cells (five mice per group). (A) Percentage of tumor-free mice at 
different time intervals. All CD11c.DOG mice DT treated and unteated  injected  with 
parental LLC cells developed palpable tumors within 2 weeks ;  instead, at the same time 50% 
of CD11c.DOG mice DT untreated and injected with LLC-CIITA cells were tumor free and in 
the corresponding mice group DT treated, 25% of mice were tumor free up to 4 weeks. (B) 
CD11c.DOG mice DT treated and untreated , injected  with parental LLC cells showed  an 
average tumore size superimposable and  strongly increased compared to corrisponding mice 
group injected with LLC-CIITA cells. Tumor size  was measured using caliper at weekly 
intervals and was expressed as a multiple of the wider and smaller tumor diameters. 
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